BAT4406F

Phase 2Small molecule

BBio-Thera Solutions

BAT4406F is one of 20 small molecule programs targeting Neuromyelitis Optica. It is currently in Phase 2.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Neuromyelitis OpticaActive, not recruiting

Neuromyelitis OpticaPhase 2

Active, not recruiting

Competition

Competitive Landscape

21 competitors in Neuromyelitis Optica

#DrugCompanyPhaseTrials

Soliris

AstraZeneca

Approved

3 2

Cellcept

Roche

Approved

3 3

UPLIZNA

HHorizon Therapeutics Ireland DAC

Approved

6 4

Imuran

LLegacy Health System

Approved

3 5

Novantrone

EMD Serono

Approved

2 6

Rayos

RRoxane Laboratories

Approved

1 7

Mesnex

BBaxter Healthcare Corporation

Approved

—8

Cytoxan

BBaxter Healthcare Corporation

Brukinsa

Darzalex

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Neuromyelitis Optica2 trials

A Phase I Clinical Trial of BAT4406F Injection in Patients With Neuromyelitis Optica Spectrum Disorders

Completed·BBio-Thera Solutions·Phase 1·NCT04146285·15 enrolled

A Clinical Trial of BAT4406F Injection in Patients With Neuromyelitis Optica Spectrum Disorders

Active, not recruiting·BBio-Thera Solutions·Phase 2·NCT06044350·162 enrolled

Sources

References

[1]
ClinicalTrials.gov — 2 trial records for BAT4406F. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — BAT4406F compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for BAT4406F. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Bio-Thera Solutions company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 2[1]
Company: BBio-Thera Solutions

BAT4406F

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Neuromyelitis Optica2 trials

References

Drug Info

Quick Facts

Related News